<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.9.2" -->
<rss version="0.92">
<channel>
	<title>Life Science Deal Flow</title>
	<link>http://clsdf.com</link>
	<description></description>
	<lastBuildDate>Sat, 24 Jul 2010 09:22:36 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>VC Series &#124; Terms &amp; Term Sheets (1)</title>
		<description><![CDATA[Good stuff here. The first ~seven minutes are intro, then comes a variety of introductory concepts related to Terms in the Term Sheet. Considering these are tech investors I thought they could do a better job with displaying the spreadsheet, but that is being knit-picky. Grab a cup of yerba mate and enjoy&#8230;

Click [HERE] to [...]]]></description>
		<link>http://clsdf.com/2010/07/vc-series-terms-term-sheets-1/</link>
			</item>
	<item>
		<title>Section 48D &#124; Qualifying Therapeutic Discovery Project Credit</title>
		<description><![CDATA[If you have not been paying attention lately, perhaps this will jar something loose&#8230;$1BILLION IN CASH GRANTS AVAILABLE FOR EMERGING LIFE SCIENCE COMPANIES aka Section 48D of the IRS code &#8220;The Qualifying Therapeutic Discovery Project Credit&#8221;. That get your attention? Good. The recently enacted healthcare reform legislation provides up to $1 billion in tax credits [...]]]></description>
		<link>http://clsdf.com/2010/05/section-48d-qualifying-therapeutic-discovery-project-credit/</link>
			</item>
	<item>
		<title>How To Create Life Science Jobs in the 21st Century</title>
		<description><![CDATA[Contribute to the Conversation at the:
Job Creation and Entrepreneurship Forum
University of Denver, The Chambers Center, the Garden Room
Friday, May 14th, 2010
2:30 pm-5:00 pm
How do we create the jobs of the 21st century? How do we create the right environment for the next generation of entrepreneurs? Creating the companies and jobs of the 21st century will [...]]]></description>
		<link>http://clsdf.com/2010/05/how-to-create-life-science-jobs-in-the-21st-century/</link>
			</item>
	<item>
		<title>RSVP Now! &#124; The 2010 GoldLab Symposium</title>
		<description><![CDATA[Hello Friends and Colleagues. Here is an event you are not going to want to miss. Admission is ***FREE*** but seats are limited! Please RSVP at http://GoldLabSymposium.com
2010 GoldLab Symposium  Time: The Crucial Fourth Dimension of Personalized Medicine
GoldLab announces the upcoming GoldLab Inaugural Symposium 2010&#8211;Time: The Crucial Fourth Dimension of Personalized Medicine scheduled for Friday, [...]]]></description>
		<link>http://clsdf.com/2010/05/rsvp-now-the-2010-goldlab-symposium/</link>
			</item>
	<item>
		<title>1Q10 OnBioVC &#124; Trend Analysis Now Available</title>
		<description><![CDATA[Hot off the press! The 1Q10 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&#38;A data too!
The 1Q10 OnBioVC Trend Analysis tracked, in aggregate, 74 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,260.1M. Compared to 1Q09 OnBioVC data, this investment activity represents a decrease in the number [...]]]></description>
		<link>http://clsdf.com/2010/04/1q10-onbiovc-trend-analysis-now-available/</link>
			</item>
	<item>
		<title>Myriad Genetics &#124; An April Fools’ that Wasn’t</title>
		<description><![CDATA[So based upon the recent ruling of Myriad Genetics (NASDAQ: MYGN) invalidation of certain patents covering the BRCA1 and BRCA2 genes, I was planning on levering the news as fodder for an all out April Fools’ post  effort, likely to have been something along the lines of ‘10,000 Gene-based Patents Overturned, Biotechnology Industry Implodes’. [...]]]></description>
		<link>http://clsdf.com/2010/04/myriad-genetics-an-april-fools%e2%80%99-that-wasn%e2%80%99t/</link>
			</item>
	<item>
		<title>2010 BioBeers Kick-off! 2 March 6:30pm</title>
		<description><![CDATA[The 2010 Season of BioBeers kicks-off on Tuesday 2 March 6:30pm. This is not your mother’s, uncle’s, brother’s BioBeers. The format has been re-engineered with the hope that you will find attending the Meetups more valuable than ever. But it takes a village to make BioBeers, that is why I urge you to visit http://www.BioBeers.com [...]]]></description>
		<link>http://clsdf.com/2010/02/2010-biobeers-kick-off-2-march-630pm/</link>
			</item>
	<item>
		<title>2009 OnBioVC &#124; Year-in-Review Trend Analysis Now Available</title>
		<description><![CDATA[I am excited to release the 2009 OnBioVC Year-in-Review Trend Analysis study. It is available for free download [HERE]; the study now features OnBioIPO and OnBioM&#38;A data too!
Bioscience venture capitalists invested $6.28 billion in 352 deals in 2009. Venture investments in 2009 represented a 3 percent increase in dollars and a 5 percent increase in [...]]]></description>
		<link>http://clsdf.com/2010/02/2009-onbiovc-year-in-review-trend-analysis-now-available/</link>
			</item>
	<item>
		<title>White Papers &#124; Biomarkers and the Biology of Web 2.0</title>
		<description><![CDATA[I’ve elected to start aggregating more content, beyond simply my posts, on Life Science Deal Flow. The starting place is interesting white papers I come across – note the new tab at the top of the LSDF site. If you have a paper you would like reviewed and shared with the LSDF community please be [...]]]></description>
		<link>http://clsdf.com/2009/12/white-papers-biomarkers-and-the-biology-of-web-2-0/</link>
			</item>
	<item>
		<title>Life Science Product Sales Status Quo &#124; Fo’getta Boud’It…</title>
		<description><![CDATA[The folks over at Deloitte are not so subtly pounding the drum about inevitable and dramatic change coming in life science sales methodologies – and are providing a rationale as to why pharma should in fact “blow up” the current sales force model. This is an important thesis to consider particularly if your entity is [...]]]></description>
		<link>http://clsdf.com/2009/11/life-science-product-sales-status-quo-fo%e2%80%99getta-boud%e2%80%99it%e2%80%a6/</link>
			</item>
	<item>
		<title>Movetis &#124; What’s a Blog to Do?</title>
		<description><![CDATA[If you select the IPO category on the drop-down box here at LifeScienceDealFlow.com one can observe the tracking of the 2009 life science initial public offering story play out – you may also note perhaps a slight bias too, that is solely coverage of the US public markets have been delivered to date. Now Belgium-based [...]]]></description>
		<link>http://clsdf.com/2009/11/movetis-what%e2%80%99s-a-blog-to-do/</link>
			</item>
	<item>
		<title>Trius Therapeutics &#124; 5 Out, 3rd in the IPO Queue</title>
		<description><![CDATA[San Diego, CA-based Trius Therapeutics is looking to potentially represent the eighth biopharma IPO of the year if they are able to get out in the next month or so. With five companies trading (see matrix below), Trius is queued up alongside Anthera Pharma and Aldagen in an effort to make their Wall St. debut.

Taking [...]]]></description>
		<link>http://clsdf.com/2009/11/trius-therapeutics-5-out-3rd-in-the-ipo-queue/</link>
			</item>
	<item>
		<title>3Q09 OnBioVC &#124; Trend Analysis Now Available</title>
		<description><![CDATA[OnBioVC.com &#8211; the sister site to Life Science Deal Flow &#8211; has released the 3Q09 Trend Analysis, the .pdf can be downloaded [HERE].

Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date!

Headquartered in Boulder, Colorado, OnBioVC provides timely coverage and comprehensive analysis of global bioscience [...]]]></description>
		<link>http://clsdf.com/2009/11/3q09-onbiovc-trend-analysis-now-available/</link>
			</item>
</channel>
</rss>
